Published in Am J Gastroenterol on March 15, 2011
State-of-the-art medical prevention of postoperative recurrence of Crohn's disease. Nat Rev Gastroenterol Hepatol (2013) 1.03
Management of Crohn's disease - are guidelines transferred to clinical practice? United European Gastroenterol J (2015) 0.81
Five-aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract (2015) 0.81
Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.80
Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study. Tech Coloproctol (2014) 0.80
Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease. Am J Gastroenterol (2011) 0.79
Current therapy of pediatric Crohn's disease. World J Gastrointest Pathophysiol (2015) 0.78
Practical medical management of Crohn's disease. ISRN Gastroenterol (2013) 0.77
Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2. Am J Physiol Gastrointest Liver Physiol (2014) 0.77
Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J (2016) 0.76
Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther (2015) 0.75
Crohn's disease: a clinical update. Therap Adv Gastroenterol (2015) 0.75
Integrative approach to analyze biodiversity and anti-inflammatory bioactivity of Wedelia medicinal plants. PLoS One (2015) 0.75
Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol (2015) 0.75
Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.75
Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther (2017) 0.75
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med (2003) 5.15
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
Functional Dyspepsia. N Engl J Med (2015) 3.66
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med (2006) 3.30
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Gastro-oesophageal reflux disease. Lancet (2006) 2.96
A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med (2006) 2.94
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology (2010) 2.83
An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol (2003) 2.83
Immune activation in patients with irritable bowel syndrome. Gastroenterology (2007) 2.82
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest (2006) 2.67
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Design of treatment trials for functional gastrointestinal disorders. Gastroenterology (2006) 2.58
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet (2003) 2.33
Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol (2008) 2.28
G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology (2004) 2.24
Minimizing postcolonoscopy abdominal pain by using CO(2) insufflation: a prospective, randomized, double blind, controlled trial evaluating a new commercially available CO(2) delivery system. Gastrointest Endosc (2002) 2.24
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology (2009) 2.19
Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol (2013) 2.18
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol (2005) 2.13
Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2012) 2.09
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm Bowel Dis (2014) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Risks of proton-pump inhibitors: what every doctor should know. Med J Aust (2009) 2.03
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study. Gastroenterology (2010) 2.01
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Does Helicobacter pylori really cause duodenal ulcers? Yes. BMJ (2009) 2.01
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
Prevalence of faecal incontinence and associated risk factors; an underdiagnosed problem in the Australian community? Med J Aust (2002) 2.00
Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr (2011) 1.96
A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology (2002) 1.94
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol (2005) 1.90
Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res (2004) 1.88
Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol (2013) 1.86
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Systematic review on the management of chronic constipation in North America. Am J Gastroenterol (2005) 1.85
EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc (2008) 1.85
Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85
Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology (2002) 1.80
Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med (2012) 1.80
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol (2006) 1.79
Gastrointestinal symptoms and glycemic control in diabetes mellitus: a longitudinal population study. Eur J Gastroenterol Hepatol (2008) 1.78
Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.78
The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77
Ulcerative colitis. BMJ (2013) 1.76
Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum (2003) 1.75
Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med (2004) 1.72
Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol (2002) 1.70